ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME

ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME

The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as sho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PEI, Lili, ZHUANG, Weiliang
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator PEI, Lili
ZHUANG, Weiliang
description The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024018243A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024018243A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024018243A13</originalsourceid><addsrcrecordid>eNrjZIhx9AvxdPJ3iVQI8XAMUQgOcHX2dPN0dvTxiVRw8vRzCVYI8VfwCPV19FNwDvFxNFFw9HNR8HV1ASrxdfULCQbzvT2BDGd_34Agz2BPP3egUa4KwUB5HgbWtMSc4lReKM3NoOzmGuLsoZtakB-fWlyQmJyal1oSHxpsZGBkYmBoYWRi7GhoTJwqAEIgMr8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME</title><source>esp@cenet</source><creator>PEI, Lili ; ZHUANG, Weiliang</creator><creatorcontrib>PEI, Lili ; ZHUANG, Weiliang</creatorcontrib><description>The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240118&amp;DB=EPODOC&amp;CC=US&amp;NR=2024018243A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240118&amp;DB=EPODOC&amp;CC=US&amp;NR=2024018243A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PEI, Lili</creatorcontrib><creatorcontrib>ZHUANG, Weiliang</creatorcontrib><title>ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME</title><description>The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIhx9AvxdPJ3iVQI8XAMUQgOcHX2dPN0dvTxiVRw8vRzCVYI8VfwCPV19FNwDvFxNFFw9HNR8HV1ASrxdfULCQbzvT2BDGd_34Agz2BPP3egUa4KwUB5HgbWtMSc4lReKM3NoOzmGuLsoZtakB-fWlyQmJyal1oSHxpsZGBkYmBoYWRi7GhoTJwqAEIgMr8</recordid><startdate>20240118</startdate><enddate>20240118</enddate><creator>PEI, Lili</creator><creator>ZHUANG, Weiliang</creator><scope>EVB</scope></search><sort><creationdate>20240118</creationdate><title>ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME</title><author>PEI, Lili ; ZHUANG, Weiliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024018243A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PEI, Lili</creatorcontrib><creatorcontrib>ZHUANG, Weiliang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PEI, Lili</au><au>ZHUANG, Weiliang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME</title><date>2024-01-18</date><risdate>2024</risdate><abstract>The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2024018243A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAME
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A41%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PEI,%20Lili&rft.date=2024-01-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024018243A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true